Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Chiron AS currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The company's active prosecution is handled by 1 distinct examiner and is located within 1 distinct art unit. This indicates a highly focused patent strategy, likely involving a single application or a very specific technical disclosure. The 1 distinct art unit involved suggests that the company's current intellectual property is concentrated in a specific technical niche within the broader biotechnology field.
The busiest examiner for this portfolio is CHENG, KAREN, who is responsible for 1 busiest examiner pending action. Because this 1 busiest examiner pending action is the only one currently active for the company, CHENG, KAREN is the sole official overseeing the prosecution. The 1 distinct art unit involved provides the technical context for the review. Resolving the 1 pending office action will require addressing the specific concerns of CHENG, KAREN. Practitioners should study the examiner's history within the assigned unit to better anticipate the requirements for moving the active matter toward a final resolution.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHENG, KAREN | 1 | 76.3% | +26.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18044613 | PHOSPHATIDYLALKANOL HOMOLOGUES HAVING LABELLED MOIETIES | CHENG, KAREN | 27d |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18044613 | PHOSPHATIDYLALKANOL HOMOLOGUES HAVING LABELLED MOIETIES | CHENG, KAREN | 1623 | §103 | Final Rejection | 27d | Pending | Mar 09, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial